[Application of cyclosporine A in myelodysplastic syndrome--review].
Treatment of myelodysplastic syndrome (MDS) remains unsatisfactory. It is possible that immunosuppressive therapy might be effective for a certain subset of patients with MDS. In this review 105 patients with MDS who were treated with cyclosporin A (CsA) including 90 RA, 5 RARS, 10 RAEB, were analyzed. The dose of CsA was 2 - 12 mg/(kg x d) for at least three months. Hematological improvement was observed in 64 patients (61%), and complete remission was observed in 14 patients (13.3%). These results indicated that CsA immunosuppressive therapy may be useful for IPSS low, intermediate-1 and intermediate-2 MDS patients.
Guan
Mei
M
Department of Hematology, Peking Union Hospital, Beijing 100730, China. Lennon007@sina.com
D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000276:immunology
D007166:Immunosuppressive Agents; D016572:Cyclosporine